SNAC2: A randomised trial of extending sentinel node based management to women with larger or multifocal breast cancers

SNAC2：一项将基于前哨淋巴结的治疗扩展到患有较大或多灶性乳腺癌的女性的随机试验

• 批准号: nhmrc : 512379
• 负责人: A/Pr Ian Campbell
• 金额: $ 84.45万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/snac2-randomised-trial-breast-cancers/97988
• 关键词: SNAC2; randomised; trial; extending; sentinel

SNAC2 extends the work begun in SNAC1, which recruited 1,088 women over 4 years. SNAC1 will determine if sentinel node biopsy causes less arm problems than axillary clearance. The goal of SNAC2 is to establish the risk of local recurrence and long term safety of sentinel node biopsy, especially for women with larger or multiple tumours. SNAC2 is needed to determine whether the smaller operation gives cure rates as good as axillary clearance. If it does, then it will become standard practice.

第二次国家妇女事务处扩大了第一次国家妇女事务处开始的工作，该次工作在四年内招募了1 088名妇女。SNAC1将确定前哨淋巴结活检是否比腋窝淋巴结清除引起更少的手臂问题。SNAC2的目标是确定前哨淋巴结活检的局部复发风险和长期安全性，特别是对于较大或多发肿瘤的女性。需要SNAC2来确定较小手术的治愈率是否与腋窝清除术一样好。如果是这样，那么它将成为标准做法。